A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Not yet recruiting · NCT04595162 · Registry updated 2020-10-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Not yet recruiting | Phase 1 | 2020-10-20 | NCT04595162 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Gracell Biotechnology Ltd. | 1 |
| Peking University Third Hospital | 243 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||